HUE052924T2 - A JAK gátló biszulfátjának kristályos formája és annak elõkészítési eljárása - Google Patents

A JAK gátló biszulfátjának kristályos formája és annak elõkészítési eljárása

Info

Publication number
HUE052924T2
HUE052924T2 HUE15849469A HUE15849469A HUE052924T2 HU E052924 T2 HUE052924 T2 HU E052924T2 HU E15849469 A HUE15849469 A HU E15849469A HU E15849469 A HUE15849469 A HU E15849469A HU E052924 T2 HUE052924 T2 HU E052924T2
Authority
HU
Hungary
Prior art keywords
bisulfate
preparation
crystal form
method therefor
jak inhibitor
Prior art date
Application number
HUE15849469A
Other languages
English (en)
Inventor
Piaoyang Sun
Guaili Wu
Xiaohui Gao
Yongjiang Chen
Lingjia Shen
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of HUE052924T2 publication Critical patent/HUE052924T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HUE15849469A 2014-10-09 2015-09-09 A JAK gátló biszulfátjának kristályos formája és annak elõkészítési eljárása HUE052924T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410529863.8A CN105566327A (zh) 2014-10-09 2014-10-09 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法

Publications (1)

Publication Number Publication Date
HUE052924T2 true HUE052924T2 (hu) 2021-06-28

Family

ID=55652569

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15849469A HUE052924T2 (hu) 2014-10-09 2015-09-09 A JAK gátló biszulfátjának kristályos formája és annak elõkészítési eljárása

Country Status (15)

Country Link
US (1) US10150770B2 (hu)
EP (1) EP3205653B1 (hu)
JP (1) JP6830888B2 (hu)
KR (1) KR20170057441A (hu)
CN (2) CN105566327A (hu)
AU (1) AU2015330554B2 (hu)
BR (1) BR112017005564A2 (hu)
CA (1) CA2963581C (hu)
DK (1) DK3205653T3 (hu)
ES (1) ES2836100T3 (hu)
HU (1) HUE052924T2 (hu)
PT (1) PT3205653T (hu)
RU (1) RU2704795C2 (hu)
TW (1) TWI675839B (hu)
WO (1) WO2016054959A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6851572B2 (ja) 2014-11-05 2021-03-31 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. Jakキナーゼ阻害剤の硫酸水素塩の結晶形およびその製造方法
JP6875407B2 (ja) * 2016-02-19 2021-05-26 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. Jakキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物
UA123709C2 (uk) * 2016-11-23 2021-05-19 Усі Форчун Фармасьютікал Ко., Лтд КРИСТАЛІЧНІ ТА СОЛЬОВІ ФОРМИ 7Н-ПІРОЛО[2,3-d]ПІРИМІДИНІВ І СПОСІБ ЇХ ОДЕРЖАННЯ
TW201827436A (zh) * 2017-01-20 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種jak激酶抑制劑的硫酸氫鹽的晶型及其製備方法
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
EP4188333A1 (en) 2020-07-28 2023-06-07 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
WO2022108911A1 (en) 2020-11-17 2022-05-27 Arcutis Biotherapeutics, Inc. Compositions and methods for deep dermal drug delivery
CN118043051A (zh) * 2021-08-12 2024-05-14 江苏恒瑞医药股份有限公司 用于治疗或预防抗宿主病的吡咯并六元杂芳物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301114A3 (en) * 2000-06-26 2004-11-29 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
JP2008526836A (ja) * 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
EP2691395B1 (en) * 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts
ES2682755T3 (es) * 2011-12-21 2018-09-21 Jiangsu Hengrui Medicine Co. Ltd. Derivado del anillo heteroarilo de seis miembros de pirrol, método de preparación del mismo y sus usos medicinales
AU2014277506B2 (en) * 2013-06-07 2017-08-31 Jiangsu Hengrui Medicine Co., Ltd. Bisulfate of Janus kinase (JAK) inhibitor and preparation method therefor

Also Published As

Publication number Publication date
US20180237438A1 (en) 2018-08-23
PT3205653T (pt) 2020-12-15
CA2963581C (en) 2022-07-12
AU2015330554A1 (en) 2017-04-27
RU2017114689A3 (hu) 2019-01-22
BR112017005564A2 (pt) 2017-12-12
ES2836100T3 (es) 2021-06-24
EP3205653A1 (en) 2017-08-16
EP3205653B1 (en) 2020-11-25
JP6830888B2 (ja) 2021-02-17
CN105980389B (zh) 2017-12-19
RU2017114689A (ru) 2018-11-14
TWI675839B (zh) 2019-11-01
RU2704795C2 (ru) 2019-10-31
KR20170057441A (ko) 2017-05-24
JP2017530146A (ja) 2017-10-12
AU2015330554B2 (en) 2020-01-02
TW201613931A (en) 2016-04-16
CA2963581A1 (en) 2016-04-14
DK3205653T3 (da) 2021-01-11
WO2016054959A1 (zh) 2016-04-14
US10150770B2 (en) 2018-12-11
CN105566327A (zh) 2016-05-11
EP3205653A4 (en) 2018-06-20
CN105980389A (zh) 2016-09-28

Similar Documents

Publication Publication Date Title
IL258276A (en) Crystal forms of beta-nicotinamide mononucleotide
ZA201703075B (en) Substituted chromanes and method of use
SG10201510712PA (en) Etchant solutions and method of use thereof
GB201514756D0 (en) Compound and method of use
IL251988A0 (en) Compounds acting on glycans and methods of using them
IL250391A0 (en) Crystalline forms of glutaminase inhibitors
GB201514760D0 (en) Compounds and method of use
PT3205653T (pt) Forma cristalina de bissulfato do inibidor da jak e seu método de preparação
EP3269719A4 (en) Crystal form of jak inhibitor and preparation method thereof
HUE050761T2 (hu) Vegyületek és alkalmazási eljárások
GB2528136B (en) User-adjustable headband and method of manufacture thereof
GB201521822D0 (en) Devices and method of operation thereof
IL253018A0 (en) Crystalline forms of apomorphine and their uses
GB201406135D0 (en) Method of etching
HUE047404T2 (hu) JAK kináz inhibitor biszulfát kristályos alakja és eljárás elõállítására
TWI563617B (en) Substrate structure and method of manufacture
EP3176814C0 (en) PHOTODETECTOR ARRANGEMENTS AND METHODS OF MAKING SAME
SG11201608466XA (en) Perforated substrate and a method of manufacture
GB201403697D0 (en) Compounds and methods of use
GB201419990D0 (en) Hprseshoe and method of manufacture
GB201416797D0 (en) Contianer and method of use thereof
GB201507707D0 (en) Components and methods for formation of components
SG10201401365VA (en) Perforated substrate and a method of manufacture